Health & Fitness
Health and Fitness
Health and Fitness
Fri, June 11, 2010
Thu, June 10, 2010 Nutra Pharma Announces Grupo Farmacéutico de Tijuana as Its Exclusive Nyloxin Distributor in Mexico
CORAL SPRINGS, FL--(Marketwire - June 10, 2010) - Nutra Pharma Corp. (
"We are pleased to announce our partnership with GFT as our exclusive Nyloxin distributor in Mexico and our very first International partner," explained [ Rik J Deitsch ], Chairman and CEO of [ Nutra Pharma Corporation ]. "GFT is a highly regarded healthcare products distributor that can provide the resources and distribution capabilities needed to successfully launch Nyloxin throughout Mexico," he concluded.
Grupo Farmacéutico de Tijuana (GFT), which was founded in 1955, currently operates two primary distribution facilities; one in Monterrey Nuevo Leon, to service midwestern and southeastern Mexico and another in the city of Tijuana to service the northwest. In addition to distributing pharmaceutical products to large, national retailers, the Company also distributes to over 3,000 pharmacies throughout Mexico.
"We are excited about our partnership with Nutra Pharma to introduce Nyloxin to Mexico. Combining the product's effectiveness with our distribution strategies will allow us to create a greater impact as we move forward with our launch," commented Enrique A. Fajardo, Managing Director of Grupo Farmacéutico de Tijuana. "This alliance will be an opportunity for both of our companies to provide an all-natural pain management solution to the Mexican consumer," he added.
In addition to partnering with GFT for Nyloxin distribution throughout Mexico, Nutra Pharma recently announced its agreement with leading healthcare products distributor, Henry Schein, for distribution of [ Nyloxin ] in the United States.
About Nutra Pharma Corp.
Nutra Pharma Corporation operates as a biotechnology company specializing in the acquisition, licensing, and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune, and infectious diseases.
The company, through its subsidiaries, carries out basic drug discovery research and clinical development, and also seeks strategic licensing partnerships to reduce the risks associated with the drug development process.
Currently, Nutra Pharma offers several drug products for sale for the treatment of pain: Cobroxin, the first over-the-counter (OTC) pain reliever clinically proven to treat moderate to severe (Stage 2) chronic pain, and Nyloxin Rx, the only non-narcotic and non-addictive treatment for severe (Stage 3) pain. Both Cobroxin and Nyloxin were developed by Nutra Pharma's wholly-owned drug discovery subsidiary, ReceptoPharm.
In addition to manufacturing Cobroxin and Nyloxin, ReceptoPharm is also developing proprietary therapeutic protein products primarily for the prevention and treatment of viral and neurological diseases, including Multiple Sclerosis (MS), Adrenomyeloneuropathy (AMN), and Human Immunodeficiency Virus (HIV), and pain in humans. Outside of its role as the drug discovery arm for Nutra Pharma, ReceptoPharm provides contract research services through its ISO class 5 and GMP certified facilities.
The company's wholly-owned medical devices subsidiary, Designer Diagnostics, engages in the research and development of diagnostic test kits designed to be used for the rapid identification of infectious diseases, such as Nontuberculous Mycobacteria (NTM).
Nutra Pharma continues to identify intellectual property and companies in the biotechnology arena as potential acquisition candidates.
[ http://www.NutraPharma.com ]
[ http://www.Nyloxin.com ]
SEC Disclaimer
This press release contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. Partnering with Grupo Farmacéutico de Tijuana for distribution in Mexico should not be construed as an indication in any way whatsoever of the future value of the Company's common stock or its financial value. The Company's filings may be accessed at the SEC's Edgar system at [ www.sec.gov ]. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.
